---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010541"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:26:47.430168+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q1 net loss $4.5M; LP-184 Phase 1a enrollment to complete by June 2025

## Summary
- Cash and equivalents $19.7M as of Mar 31, 2025, down from $24.0M at Dec 31, 2024.
- Net loss $4.5M ($0.42/share) vs $5.4M ($0.51/share) in Q1 2024; R&D expense $3.3M vs $4.3M.
- LP-184 Phase 1a solid tumor trial enrollment expected to finish by end of June 2025; full data readout in Q3 2025.
- FDA cleared Phase 1b/2 protocols for LP-184 in TNBC (with olaparib) and STK11/KEAP1-mutant NSCLC.
- LP-300 HARMONIC trial additional data including Asian expansion cohort anticipated in Q3 2025.

## SEC filing metadata
- accession: 0001641172-25-010541
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000164117225010541/0001641172-25-010541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000164117225010541/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010541
- JSON: https://secwatch.observer/filing/0001641172-25-010541.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.